Spirooxadiazoline-oxindoles derived from imatinib show antimyeloproliferative potential in K562 cells.
PAPP
chronic myeloid leukemia
imatinib
spiro‐oxindoles
tyrosine kinase inhibitors
Journal
Archiv der Pharmazie
ISSN: 1521-4184
Titre abrégé: Arch Pharm (Weinheim)
Pays: Germany
ID NLM: 0330167
Informations de publication
Date de publication:
16 Apr 2024
16 Apr 2024
Historique:
revised:
15
03
2024
received:
10
01
2024
accepted:
29
03
2024
medline:
17
4
2024
pubmed:
17
4
2024
entrez:
16
4
2024
Statut:
aheadofprint
Résumé
Imatinib mesylate was the first representative BCR-ABL1 tyrosine kinase inhibitor (TKI) class for the treatment of chronic myeloid leukemia. Despite the revolution promoted by TKIs in the treatment of this pathology, a resistance mechanism occurs against all BCR-ABL1 inhibitors, necessitating a constant search for new therapeutic options. To develop new antimyeloproliferative substances, we applied a medicinal chemistry tool known as molecular hybridization to design 25 new substances. These compounds were synthesized and biologically evaluated against K562 cells, which express BCR-ABL1, a constitutively active tyrosine kinase enzyme, as well as in WSS-1 cells (healthy cells). The new compounds are conjugated hybrids that contain phenylamino-pyrimidine-pyridine (PAPP) and an isatin backbone, which are the main pharmacophoric fragments of imatinib and sunitinib, respectively. A spiro-oxindole nucleus was used as a linker because it occurs in many compounds with antimyeloproliferative activity. Compounds 2a, 2b, 3c, 4c, and 4e showed promise, as they inhibited cell viability by between 45% and 61% at a concentration of 10 µM. The CC
Identifiants
pubmed: 38627294
doi: 10.1002/ardp.202400029
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2400029Subventions
Organisme : Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro
Organisme : Conselho Nacional de Desenvolvimento Científico e Tecnológico
Informations de copyright
© 2024 Deutsche Pharmazeutische Gesellschaft.
Références
T. G. Knight, M. R. Grunwald, E. Copelan, Chronic Myeloid Leukemia (CML). In Concise Guide to Hematology (Eds: H. M. Lazarus, A. H. Schmaier), Springer International Publishing AG, Cham 2019, pp. 313.
D. J. L. Joske, Med. J. Aust. 2008, 189, 277. https://doi.org/10.5694/j.1326-5377.2008.tb02027.x
C. G. Geary, Br. J. Haematol. 2000, 110, 2. https://doi.org/10.1046/j.1365-2141.2000.02137.x
J. Groffen, J. Stephenson, N. Heisterkamp, A. Deklein, C. Bartram, G. Grosveld, Cell 1984, 36, 93. https://doi.org/10.1016/0092-8674(84)90077-1
P. C. Nowell, D. A. Hungerford, J. Natl. Cancer Inst. 1961, 27, 1013. https://doi.org/10.1093/jnci/27.5.1013
B. J. Druker, C. L. Sawyers, H. Kantarjian, D. J. Resta, S. F. Reese, J. M. Ford, R. Capdeville, M. Talpaz, N. Engl. J. Med. 2001, 344, 1038. https://doi.org/10.1056/NEJM200104053441402
T. G. Lugo, A. M. Pendergast, A. J. Muller, O. N. Witte, Science 1990, 247, 1079. https://doi.org/10.1126/science.2408149
E. Jabbour, J. E. Cortes, F. J. Giles, S. O'Brien, H. M. Kantarjian, Cancer 2007, 109, 2171. https://doi.org/10.1002/cncr.22661
R. Bitencourt, I. Zalcberg, I. D. Louro, Rev. Bras. Hematol. Hemoter. 2011, 33(6), 470. https://doi.org/10.5581/1516-8484.20110124
E. Berman, S. Jhanwar, C. Hedvat, M. E. Arcila, O. A. Wahab, R. Levine, M. Maloy, W. Ma, M. Albitar, Leuk. Res. 2016, 49, 108. https://doi.org/10.1016/j.leukres.2016.08.006
T. O'Hare, C. A. Eide, M. W. N. Deininger, Blood 2007, 110(7), 2242. https://doi.org/10.1182/blood-2007-03-066936
D. Milojkovic, J. Apperley, Clin. Cancer Res. 2009, 15(24), 7519. https://doi.org/10.1158/1078-0432.CCR-09-1068
V. W. T. Ho, Y. Tan, N. Wang, Y. Feng, Cancer Management by Tyrosine Kinase Inhibitors: Efficacy, Limitation, and Future Strategies, Tyrosine Kinases as Druggable Targets in Cancer. IntechOpen, 2019. https://doi.org/10.5772/intechopen.82513
T. P. Hughes, N. Shanmuganathan, Hematology 2022, 2022, 129. https://doi.org/10.1182/hematology.2022000328
L. D. Azevedo, M. M. Bastos, F. C. Vasconcelos, L. V. B. Hoelz, F. P. S. Junior, R. F. Dantas, A. C. M. de Almeida, A. P. de Oliveira, L. C. Gomes, R. C. Maia, N. Boechat, Med. Chem. Res. 2017, 26, 2929. https://doi.org/10.1007/s00044-017-1993-8
N. Boechat, W. Kover, V. Bongertz, M. Bastos, N. Romeiro, M. Azevedo, W. Wollinger, Med. Chem. 2007, 3, 533. https://doi.org/10.2174/157340607782360326
F. S. Castelo‐Branco, E. C. De Lima, J. L. O. Domingos, A. C. Pinto, M. C. S. Lourenço, K. M. Gomes, M. M. Costa‐Lima, C. F. Araujo‐Lima, C. A. F. Aiub, I. Felzenszwalb, T. E. M. M. Costa, C. Penido, M. G. Henriques, N. Boechat, Eur. J. Med. Chem. 2018, 146, 529. https://doi.org/10.1016/j.ejmech.2018.01.071
N. Boechat, M. M. Bastos, T. M. L. Souza, D. I. Leite, A. M. R. Bernardino, WO2017193180A1, 2017.
L. Q. M. Chow, S. G. Eckhardt, J. Clin. Oncol. 2007, 25(7), 884. https://doi.org/10.1200/JCO.2006.06.3602
Z. Ansari, M. K. George, J. Med. Case. Rep. 2013, 7, 54. https://doi.org/10.1186/1752-1947-7-54
S. Shukla, R. W. Robey, S. E. Bates, S. V. Ambudkar, Drug Metab. Dispos. 2009, 37(2), 359.
T. Illmer, M. Schaich, U. Platzbecker, J. Freiberg‐Richter, U. Oelschlägel, M. von Bonin, S. Pursche, T. Bergemann, G. Ehninger, E. Schleyer, Leukemia 2004, 18(3), 401. https://doi.org/10.1038/sj.leu.2403257
M. Ozkan, B. Kaymaz, A. Gunes, B. Can, N. Soyer, A. Yilmaz, F. Vural, F. Sahin, G. Saydam, J. Cancer Res. Ther. 2020, 16, 150. https://doi.org/10.4103/jcrt.JCRT_983_17
Q. Zhang, Y. Teng, Y. Yuan, T. Ruan, Q. Wang, X. Gao, Y. Zhou, K. Han, P. Yu, K. Lu, Eur. J. Med. Chem. 2018, 156, 800. https://doi.org/10.1016/j.ejmech.2018.07.032
A. Oliveira, S. Moura, L. Pimentel, J. Neto, R. Dantas, F. Silva‐Jr, M. Bastos, N. Boechat, Molecules 2022, 27, 750. https://doi.org/10.3390/molecules2703075
L.‐M. Zhou, R.‐Y. Qu, G.‐F. Yang, Expert Opin. Drug Discov. 2020, 15(5), 603. https://doi.org/10.1080/17460441.2020.1733526
N. R. Ball‐Jones, J. J. Badillo, A. K. Franz, Org. Biomol. Chem. 2012, 10, 5165. https://doi.org/10.1039/C2OB25184A
C. V. Galliford, K. A. Scheidt, Angew. Chem. Int. Ed. 2007, 46, 8748. https://doi.org/10.1002/anie.200701342
L. Hong, R. Wang, Adv. Synth. Catal. 2013, 355, 1023. https://doi.org/10.1002/adsc.201200808
F. Lovering, J. Bikker, C. Humblet, J. Med. Chem. 2009, 52, 6752. https://doi.org/10.1021/jm901241e
W. Wei, S. Cherukupalli, L. Jing, X. Liu, P. Zhan, Drug Discov. Today 2020, 25(10), 1839. https://doi.org/10.1016/j.drudis.2020.07.017
K. Hiesinger, D. Dar'in, E. Proschak, M. Krasavin, J. Med. Chem. 2021, 64, 150. https://doi.org/10.1021/acs.jmedchem.0c01473
B. Yu, D. Q. Yu, H. M. Liu, Eur. J. Med. Chem. 2015, 97, 673. https://doi.org/10.1016/j.ejmech.2014.06.056
R. S. Tumskiy, G. L. Burygin, A. A. Anis'kov, I. N. Klochkova, Pharmacol. Rep. 2019, 71(2), 357. https://doi.org/10.1016/j.pharep.2018.12.004
C. J. A. Ribeiro, J. D. Amaral, C. M. P. Rodrigues, R. Moreira, M. M. M. Santos, MedChemComm 2016, 7, 420. https://doi.org/10.1039/C5MD00450K
R. Miethchen, J. Fluorine Chem. 2004, 125, 895. https://doi.org/10.1016/j.jfluchem.2004.01.015
S. Zhao, K. Li, Y. Jin, J. Lin, Eur. J. Med. Chem. 2018, 144, 41. https://doi.org/10.1016/j.ejmech.2017.12.016
I. Rawal, RSC Adv. 2015, 5, 4135. https://doi.org/10.1039/C4RA14696D
K. Kitahara, T. Toma, J. Shimokawa, T. Fukuyama, Org. Lett. 2008, 10(11), 2259. https://doi.org/10.1021/ol800677p
E. P. Gillis, K. J. Eastman, M. D. Hill, D. J. Donnelly, N. A. Meanwell, J. Med. Chem. 2015, 58, 8315. https://doi.org/10.1021/acs.jmedchem.5b00258
W. K. Hagmann, J. Med. Chem. 2008, 51(15), 4359. https://doi.org/10.1021/jm800219f
H. Mei, J. Han, S. Fustero, M. Medio‐Simon, D. M. Sedgwick, C. Santi, R. Ruzziconi, V. A. Soloshonok, Chem. Eur. J. 2019, 25, 11797. https://doi.org/10.1002/chem.201901840
I. V. Tetko, V. Y. Tanchuk, J. Chem. Inf. Comput. Sci. 2002, 42(5), 1136. https://doi.org/10.1021/ci025515j
K. Singh, A. Gangrade, A. Jana, B. B. Mandal, N. Das, ACS Omega 2019, 4, 835. https://doi.org/10.1021/acsomega.8b02849
R. B. Badisa, S. F. Darling‐reed, P. Joseph, J. S. Cooperwood, L. M. Latinwo, C. B. Goodman, Anticancer Res. 2009, 29, 2993.
D. Saftić, B. Žinić, L. Glavaš‐Obrovac, M. Studzińska, E. Paradowska, Z. J. Leśnikowski, Nucleosides Nucleotides Nucl. Acids 2018, 37(7), 397. https://doi.org/10.1080/15257770.218.1485932
H. Sharghi, M. H. Sarvari, Synlett 2001, 1, 99.
X. Jiang, X. Xu, Y. Lin, Y. Yan, P. Li, R. Bai, Y. Xie, Tetrahedron 2018, 74, 5879.
K. Kitahara, T. Toma, J. Shimokawa, T. Fukuyama, Org. Lett. 2008, 10(11), 2259.
Pooja, S. Aggarwal, A. K. Tiwari, V. Kumar, R. Pratap, G. Singhb, A. K. Mishra, RSC Adv. 2015, 5, 23471.